Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

Katherine A. Janeway, Karen H. Albritton, Annick D. Van Den Abbeele, Gina Z. D'Amato, Paolo Pedrazzoli, Salvatore Siena, Joel Picus, James E. Butrynski, Marcus Schlemmer, Michael Heinrich, George D. Demetri

    Research output: Contribution to journalArticle

    98 Citations (Scopus)

    Abstract

    Background. Sunitinib inhibits KIT and other members of the split-kinase-domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. Procedure. Sunitinib therapy was provided through a treatment-use protocol. Patients were 10-17 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6-week treatment cycles. KIT and platelet-derived growth factor receptor alpha (PDGFRA) genotyping of tumor tissue were performed. Results. One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1-2. None of the five patients tested had mutations in KIT or PDGFRA. Conclusion. Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib-resistant GIST.

    Original languageEnglish (US)
    Pages (from-to)767-771
    Number of pages5
    JournalPediatric Blood and Cancer
    Volume52
    Issue number7
    DOIs
    StatePublished - Jul 1 2009

    Fingerprint

    Gastrointestinal Stromal Tumors
    Pediatrics
    Therapeutics
    Platelet-Derived Growth Factor alpha Receptor
    sunitinib
    Imatinib Mesylate
    Receptor Protein-Tyrosine Kinases
    Clinical Protocols
    Neoplasms
    Phosphotransferases

    Keywords

    • Clinical trials
    • Drug resistance
    • New agents
    • Pediatric oncology
    • Soft tissue sarcoma

    ASJC Scopus subject areas

    • Oncology
    • Pediatrics, Perinatology, and Child Health
    • Hematology

    Cite this

    Janeway, K. A., Albritton, K. H., Van Den Abbeele, A. D., D'Amato, G. Z., Pedrazzoli, P., Siena, S., ... Demetri, G. D. (2009). Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatric Blood and Cancer, 52(7), 767-771. https://doi.org/10.1002/pbc.21909

    Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. / Janeway, Katherine A.; Albritton, Karen H.; Van Den Abbeele, Annick D.; D'Amato, Gina Z.; Pedrazzoli, Paolo; Siena, Salvatore; Picus, Joel; Butrynski, James E.; Schlemmer, Marcus; Heinrich, Michael; Demetri, George D.

    In: Pediatric Blood and Cancer, Vol. 52, No. 7, 01.07.2009, p. 767-771.

    Research output: Contribution to journalArticle

    Janeway, KA, Albritton, KH, Van Den Abbeele, AD, D'Amato, GZ, Pedrazzoli, P, Siena, S, Picus, J, Butrynski, JE, Schlemmer, M, Heinrich, M & Demetri, GD 2009, 'Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib', Pediatric Blood and Cancer, vol. 52, no. 7, pp. 767-771. https://doi.org/10.1002/pbc.21909
    Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatric Blood and Cancer. 2009 Jul 1;52(7):767-771. https://doi.org/10.1002/pbc.21909
    Janeway, Katherine A. ; Albritton, Karen H. ; Van Den Abbeele, Annick D. ; D'Amato, Gina Z. ; Pedrazzoli, Paolo ; Siena, Salvatore ; Picus, Joel ; Butrynski, James E. ; Schlemmer, Marcus ; Heinrich, Michael ; Demetri, George D. / Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. In: Pediatric Blood and Cancer. 2009 ; Vol. 52, No. 7. pp. 767-771.
    @article{0ceaaf244d6146e199c628014ae10dff,
    title = "Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib",
    abstract = "Background. Sunitinib inhibits KIT and other members of the split-kinase-domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. Procedure. Sunitinib therapy was provided through a treatment-use protocol. Patients were 10-17 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6-week treatment cycles. KIT and platelet-derived growth factor receptor alpha (PDGFRA) genotyping of tumor tissue were performed. Results. One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1-2. None of the five patients tested had mutations in KIT or PDGFRA. Conclusion. Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib-resistant GIST.",
    keywords = "Clinical trials, Drug resistance, New agents, Pediatric oncology, Soft tissue sarcoma",
    author = "Janeway, {Katherine A.} and Albritton, {Karen H.} and {Van Den Abbeele}, {Annick D.} and D'Amato, {Gina Z.} and Paolo Pedrazzoli and Salvatore Siena and Joel Picus and Butrynski, {James E.} and Marcus Schlemmer and Michael Heinrich and Demetri, {George D.}",
    year = "2009",
    month = "7",
    day = "1",
    doi = "10.1002/pbc.21909",
    language = "English (US)",
    volume = "52",
    pages = "767--771",
    journal = "Pediatric Blood and Cancer",
    issn = "1545-5009",
    publisher = "Wiley-Liss Inc.",
    number = "7",

    }

    TY - JOUR

    T1 - Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

    AU - Janeway, Katherine A.

    AU - Albritton, Karen H.

    AU - Van Den Abbeele, Annick D.

    AU - D'Amato, Gina Z.

    AU - Pedrazzoli, Paolo

    AU - Siena, Salvatore

    AU - Picus, Joel

    AU - Butrynski, James E.

    AU - Schlemmer, Marcus

    AU - Heinrich, Michael

    AU - Demetri, George D.

    PY - 2009/7/1

    Y1 - 2009/7/1

    N2 - Background. Sunitinib inhibits KIT and other members of the split-kinase-domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. Procedure. Sunitinib therapy was provided through a treatment-use protocol. Patients were 10-17 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6-week treatment cycles. KIT and platelet-derived growth factor receptor alpha (PDGFRA) genotyping of tumor tissue were performed. Results. One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1-2. None of the five patients tested had mutations in KIT or PDGFRA. Conclusion. Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib-resistant GIST.

    AB - Background. Sunitinib inhibits KIT and other members of the split-kinase-domain family of receptor tyrosine kinases. Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib. Procedure. Sunitinib therapy was provided through a treatment-use protocol. Patients were 10-17 years old at enrollment. All patients had GIST resistant to imatinib therapy. Sunitinib was administered daily for 4 weeks in 6-week treatment cycles. KIT and platelet-derived growth factor receptor alpha (PDGFRA) genotyping of tumor tissue were performed. Results. One patient achieved a partial response, five patients had stable disease and one patient had progressive disease on sunitinib. The duration of disease stabilization was between 7 and 21+ months, with a mean of 15 months. Time to tumor progression was longer on sunitinib than on prior imatinib treatment for five of six patients. Two patients experienced grade 3 adverse events. All other adverse events were grade 1-2. None of the five patients tested had mutations in KIT or PDGFRA. Conclusion. Sunitinib treatment was associated with substantial initial antitumor activity and acceptable tolerability in this group of pediatric patients with imatinib-resistant GIST.

    KW - Clinical trials

    KW - Drug resistance

    KW - New agents

    KW - Pediatric oncology

    KW - Soft tissue sarcoma

    UR - http://www.scopus.com/inward/record.url?scp=67650472798&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=67650472798&partnerID=8YFLogxK

    U2 - 10.1002/pbc.21909

    DO - 10.1002/pbc.21909

    M3 - Article

    C2 - 19326424

    AN - SCOPUS:67650472798

    VL - 52

    SP - 767

    EP - 771

    JO - Pediatric Blood and Cancer

    JF - Pediatric Blood and Cancer

    SN - 1545-5009

    IS - 7

    ER -